Bryan C.  Hanson net worth and biography

Bryan Hanson Biography and Net Worth

EVP of Medtronic
Bryan C. Hanson was appointed President and Chief Executive Officer and a member of the Board of Directors of Zimmer Biomet in December 2017. He was appointed Chairman of the Board in 2021.

Prior to joining Zimmer Biomet, Mr. Hanson served as a member of Medtronic’s Executive Committee and as Executive Vice President and Group President, Minimally Invasive Therapies Group of Medtronic, where he oversaw and provided strategic direction to that approximately $9 billion business.  Prior to joining Medtronic, Mr. Hanson served as Group President, Covidien, with global responsibility for all Covidien business segments.  Prior to being elevated to that newly created position, Mr. Hanson served as Group President, Medical Devices & U.S. of Covidien and prior to that, he served as Group President, Surgical Solutions and President, Energy-based Devices.  Mr. Hanson began his career with Covidien in 1992.  He holds a Bachelor of Science degree in Finance from Florida State University.  He also completed the Kellogg School of Management Finance for Executives program in 2010 and the Harvard Executive Education in Leadership program in 2013.  Mr. Hanson serves on the board of AmeriCares, an emergency response and global health organization committed to saving lives and building healthier futures for people in crisis.  

What is Bryan C. Hanson's net worth?

The estimated net worth of Bryan C. Hanson is at least $4.32 million as of May 13th, 2020. Mr. Hanson owns 54,568 shares of Medtronic stock worth more than $4,321,240 as of April 19th. This net worth estimate does not reflect any other assets that Mr. Hanson may own. Learn More about Bryan C. Hanson's net worth.

How do I contact Bryan C. Hanson?

The corporate mailing address for Mr. Hanson and other Medtronic executives is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. Medtronic can also be reached via phone at (531) 438-1700 and via email at [email protected]. Learn More on Bryan C. Hanson's contact information.

Has Bryan C. Hanson been buying or selling shares of Medtronic?

Bryan C. Hanson has not been actively trading shares of Medtronic during the last ninety days. Learn More on Bryan C. Hanson's trading history.

Who are Medtronic's active insiders?

Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.

Are insiders buying or selling shares of Medtronic?

During the last year, insiders at the medical technology company sold shares 8 times. They sold a total of 56,412 shares worth more than $4,783,509.24. The most recent insider tranaction occured on April, 8th when EVP Michael Marinaro sold 854 shares worth more than $71,001.56. Insiders at Medtronic own 0.3% of the company. Learn More about insider trades at Medtronic.

Information on this page was last updated on 4/8/2024.

Bryan C. Hanson Insider Trading History at Medtronic

See Full Table

Bryan C. Hanson Buying and Selling Activity at Medtronic

This chart shows Bryan C. Hanson's buying and selling at Medtronic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medtronic Company Overview

Medtronic logo
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $79.19
Low: $78.43
High: $79.30

50 Day Range

MA: $84.04
Low: $79.08
High: $87.15

2 Week Range

Now: $79.19
Low: $68.84
High: $92.02

Volume

6,063,267 shs

Average Volume

6,315,096 shs

Market Capitalization

$105.15 billion

P/E Ratio

25.22

Dividend Yield

3.48%

Beta

0.76